Author

Nick Forward

Institution: Queen Elizabeth II Health Sciences Centre

Observed institution: Queen Elizabeth II Health Sciences Centre

OpenAlex ID: A5067286472

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.

2024 · Jeong A Kim, Uwe Hahn, et al. · Journal of Clinical Oncology · 5

Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial

2024 · Arjun Pandey, Kim Roos, et al. · eJHaem · 2

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

2020 · Neil Berinstein, Isabelle Bence-Bruckler, et al. · Regular and Young Investigator Award Abstracts

Works count: 3

Citation count: 7

H-index: 2

I10-index: